Free Trial
NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

Sonoma Pharmaceuticals logo
$2.39 -0.03 (-1.24%)
Closing price 02/21/2025 03:46 PM Eastern
Extended Trading
$2.37 -0.02 (-0.84%)
As of 02/21/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)

Key Stats

Today's Range
$2.32
$2.47
50-Day Range
$2.39
$2.84
52-Week Range
$2.30
$9.37
Volume
39,279 shs
Average Volume
50,978 shs
Market Capitalization
$3.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Sonoma Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

SNOA MarketRank™: 

Sonoma Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Sonoma Pharmaceuticals.

  • Earnings Growth

    Earnings for Sonoma Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($1.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sonoma Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sonoma Pharmaceuticals is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sonoma Pharmaceuticals has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.61% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently increased by 75.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Sonoma Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Sonoma Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.61% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently increased by 75.11%, indicating that investor sentiment is decreasing significantly.
  • MarketBeat Follows

    2 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.90% of the stock of Sonoma Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.

  • Read more about Sonoma Pharmaceuticals' insider trading history.
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Stock News Headlines

Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines
See More Headlines

SNOA Stock Analysis - Frequently Asked Questions

Sonoma Pharmaceuticals' stock was trading at $2.69 at the start of the year. Since then, SNOA shares have decreased by 11.2% and is now trading at $2.39.
View the best growth stocks for 2025 here
.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its earnings results on Wednesday, February, 5th. The company reported ($0.59) earnings per share for the quarter. Sonoma Pharmaceuticals had a negative net margin of 26.82% and a negative trailing twelve-month return on equity of 68.98%.

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Meta Platforms (META), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Ford Motor (F) and PayPal (PYPL).

Company Calendar

Last Earnings
2/05/2025
Today
2/22/2025
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SNOA
Employees
180
Year Founded
1999

Profitability

Net Income
$-4,840,000.00
Pretax Margin
-26.75%

Debt

Sales & Book Value

Annual Sales
$12.73 million
Book Value
$3.01 per share

Miscellaneous

Free Float
1,553,000
Market Cap
$3.87 million
Optionable
Not Optionable
Beta
1.43

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:SNOA) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners